ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

5 links0 made here, not in the record10 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06719973Phase 1 Study of M9466Combined With Carboplatinand Platinum-basedAnticancer Therapy (DDRiver521)EMD Serono Research & DevelopmPhase 1 · withdrawnRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSAdvanced Solid TumorsNo longer in the registry's filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseDRUGSPARP1 Inhibitor HRS-1167Entry “M9466”, read by our name rule›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedNov 18 · Rule based · BackgroundBackgroundCarboplatinIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundEtoposideIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAtezolizumabIntervention entry›Nov 3 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partner

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

PARP1 Inhibitor HRS-1167

From the registry record3 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “M9466”the record gives no role
→judged=agrees→changed
How the 3 judgments split33%of judgments with a known value say Background
Background · 1
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 3PARP1 Inhibitor HRS-1167Claude Opus 5.5TestedCurrent
Nov 3CarboplatinClaude Opus 5.5BackgroundCurrent
Nov 3EtoposideClaude Opus 5.5BackgroundCurrent
Nov 3AtezolizumabClaude Opus 5.5Background · partnerCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 14Advanced Solid TumorsRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 18PARP1 Inhibitor HRS-1167Rule based · role ruleTestedAgrees
Nov 18PARP1 Inhibitor HRS-1167Rule based · role ruleBackgroundCurrent
Nov 18CarboplatinRule based · role ruleBackgroundAgrees
Nov 18EtoposideRule based · role ruleBackgroundAgrees
Nov 18AtezolizumabRule based · role ruleBackgroundAgrees

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.